Synapse

← BMJ Oncology

Papers in BMJ Oncology

Page 4 · newest first

  1. Feasibility of implementing a rapid-learning methodology to inform radiotherapy treatments: key professional stakeholders’ viewsBMJ Oncology · 2024
  2. Challenges faced by women oncologists in Africa: a mixed methods studyBMJ Oncology · 2024
  3. Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trialsBMJ Oncology · 2024
  4. HealthCare Access Barrier (HCAB) framework for the barriers to cancer care during conflicts: perspective from IraqBMJ Oncology · 2024
  5. Embracing rapid learning in radiotherapy: feasible and acceptable with stakeholder corroborationBMJ Oncology · 2024
  6. Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid reviewBMJ Oncology · 2024
  7. Accuracy of screening tests for cervical precancer in women living with HIV in low-resource settings: a paired prospective study in Lusaka, ZambiaBMJ Oncology · 2024
  8. Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunityBMJ Oncology · 2024
  9. Identifying the deficits in cancer care for people with intellectual disabilitiesBMJ Oncology · 2024
  10. Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapyBMJ Oncology · 2024
  11. Cervical cancer screening using tests that provide same-day results: a study of test accuracyBMJ Oncology · 2024
  12. Machine learning predicted fast progression after initiation of immune checkpoint inhibitors in advanced non-small cell lung cancerBMJ Oncology · 2024
  13. Artificial intelligence across oncology specialties: current applications and emerging toolsBMJ Oncology · 2024
  14. Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spendingBMJ Oncology · 2024
  15. Multi-cancer early detection tests: a strategy for improvementBMJ Oncology · 2024
  16. Repurposing radiosensitising medicines for radiotherapy: an overviewBMJ Oncology · 2024
  17. ‘Godrevy Project’: virtual reality for symptom control and well-being in oncology and palliative care – a non-randomised pre-post interventional trialBMJ Oncology · 2023
  18. Benefits and harms of breast cancer screening revisited: a large, retrospective cross-sectional study quantifying treatment intensity in women with screen-detected versus non-screen-detected cancer in Australia and New ZealandBMJ Oncology · 2023
  19. Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trialBMJ Oncology · 2023
  20. Boosting and broadening recruitment to UK cancer trials: towards a blueprint for actionBMJ Oncology · 2023
  21. PACT-UK (PAncreatic Cancer reporting Template–UK): a cross-specialty multi-institutional consensus panel development of a standardised radiological reporting proforma for pancreatic cancerBMJ Oncology · 2023
  22. How do tumours outside the gastrointestinal tract respond to dietary fibre supplementation?BMJ Oncology · 2023
  23. Closing the gaps in recruitment and retention in cancer trials: sufficient evidence but poor implementationBMJ Oncology · 2023
  24. Cardiovascular health: an important component of cancer survivorshipBMJ Oncology · 2023
  25. The English National Lynch Syndrome transformation project: an NHS Genomic Medicine Service Alliance (GMSA) programmeBMJ Oncology · 2023
  26. NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08)BMJ Oncology · 2023
  27. Transforming the care of people with Lynch syndrome: a system-wide approachBMJ Oncology · 2023
  28. Globalisation of industry-sponsored clinical trials for breast, lung and colon cancer research: trends, threats and opportunitiesBMJ Oncology · 2023
  29. Globalisation of clinical trials in oncology: a double-edged sword?BMJ Oncology · 2023
  30. Treatment-related acute toxicity with adjuvant systemic treatment among patients with HER2-positive early invasive breast cancer: a national population-based cohort studyBMJ Oncology · 2023
  31. Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort studyBMJ Oncology · 2023
  32. Use of immunosuppression and subsequent cancer incidence: cohort studyBMJ Oncology · 2023
  33. Guilty by association? The complex relationship between immunosuppressants and cancerBMJ Oncology · 2023
  34. Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019BMJ Oncology · 2023
  35. Long-term opioid therapy trajectories and overdose in patients with and without cancerBMJ Oncology · 2023
  36. Shifting tides: the rising tide of early-onset cancers demands attentionBMJ Oncology · 2023
  37. Making administrative healthcare systems clinical data the future of clinical trials: lessons from BladderPathBMJ Oncology · 2023
  38. Community-generated solutions to cancer inequity: recommendations from transgender, non-binary and intersex people on improving cancer screening and careBMJ Oncology · 2023
  39. Inclusive oncological trials and targeted treatments cannot ignore sex and genderBMJ Oncology · 2023
  40. Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gapsBMJ Oncology · 2023
  41. Modern cancer trials still lack information about QoL impacts on patientsBMJ Oncology · 2023
  42. Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research studyBMJ Oncology · 2023
  43. COVID-19 and cancer in the UK: which will prove to be the lesser of two evils?BMJ Oncology · 2023
  44. Bridging the gap: promoting equity and diversity in global oncology research within Sub-Saharan AfricaBMJ Oncology · 2023